SAN FRANCISCO, CA--(Marketwire - April 28, 2011) -
| Highlighted Links |
|
|
Robust growth in Latin American economies is driving strong demand for pharmaceuticals, sales of which are expected to post double-digit growth in the region through 2014. Pharmaceutical companies are seizing the opportunity to expand in Brazil, Argentina, Chile, and beyond, but not without policy, pricing, and reimbursement challenges.
Burrill & Company’s Latin America Life Sciences Conference, to be held May 19-20, 2011 in Rio De Janeiro, Brazil, will examine the challenges and opportunities that companies face when doing business in Latin America.
Among the panelists discussing these issues will be:
- Pedro Palmeira, Executive Director, PROFARMA, BNDES
- Bill Burkoth, Senior Director, Pfizer Venture Investment
- Dr. Jaderson Lima, Medical and Scientific Alliances Director, Sanofi-Aventis
- Ogari Pacheco, CEO, Cristália Laboratory
A complimentary copy of the April issue of The Burrill Report, featuring a special focus on Life Sciences in Latin America, will be distributed to attendees upon completion of their registration for The Burrill Latin America Life Sciences Conference. In addition to the comprehensive quarter wrap-up of financial activity, partnering, and industry developments, the issue includes stories on:
- Government Incentives for Biopharmas
- Challenges Novartis Faces in Commercializing its Blood Screening Test in Brazil
- The Biofuels Boom in Brazil
- Dealmaking in Latin America
The conference will bring together corporate executives, financiers, regulators, government officials and academic leaders from around the world to discuss the current state of life sciences with industry leaders in Latin America. To register for this event and obtain your complimentary copy of The Burrill Report, please visit www.burrillandco.com/Latin_America_2011/.
About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm’s businesses include venture capital, private equity, merchant banking and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia. For more information visit: www.burrillandco.com.
Media Relations:
Peter Winter
Email Contact
415-591-5474
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
